qPCR for BoNT Type-Specific PXD101 Detection The qPCR assay consisted of seven separate reactions, each specific for one of the seven neurotoxin gene types. For absolute quantification, template standards for each of the neurotoxin gene types were run alongside

the DNA samples for each of the seven qPCRs. qPCR conditions were as follows: 95°C for 5 minutes, then 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. PCR reaction mixture contained PCR Buffer, 3.5 uM MgCl2, 200 nM dNTPs, 500 nM forward or reverse primer, 200 nM Fam/BHQ1-labeled probe, 3 nM BD636 reference dye, 0.25 U Taq Polymerase (Invitrogen Corp, Carlsbad, CA). 5 μL of purified DNA or plasmid standard was used in each 25 μL PCR reaction. Based on cycle of threshold (Ct) values with known copy numbers of plasmid in each reaction, a standard curve is generated that will be used to calculate the values of unknown samples. Acknowledgements We would like to thank Dr. David Kulesh from USAMRIID for his expert technical advice and the use of equipment. We would also https://www.selleckchem.com/products/shp099-dihydrochloride.html like to

thank Dr. Nir Dover for extracting and providing fecal DNA from the California patient with infant botulism. We also thank Alma Boritz for contributing a healthy infant stool sample. The opinions, interpretations and recommendations are those of the author and are not necessarily those of the US Army. References 1. Metabolism inhibitor Montecucco C: Clostridial neurotoxins: the molecular pathogenesis of tetanus and botulism. Current Topics of Microbial immunology 1995, 195:1–278. 2. Gill DM: Bacterial Regorafenib chemical structure toxins: a table of lethal amounts. Microbiol Rev 1982,46(1):86–94.PubMed 3. Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 2005,5(3):274–279.PubMedCrossRef 4. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al.: Botulinum toxin as a biological weapon: medical and public health management. Jama 2001,285(8):1059–1070.PubMedCrossRef 5. Centers for Disease Control C: Centers for Disease Control and Prevention: Botulism

in the United States, 1899–1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers, Atlanta, GA. Centers for Disease Control and Prevention; 1998. 6. Koepke RJS, Arnon SS: Global Occurrence of Infant Botulism, 1976–2006. Pediatrics 2008, in press. 7. Akbulut D, Dennis J, Gent M, Grant KA, Hope V, Ohai C, McLauchlin J, Mithani V, Mpamugo O, Ncube F, et al.: Wound botulism in injectors of drugs: upsurge in cases in England during 2004. Euro Surveill 2005,10(9):172–174.PubMed 8. Artin I, Bjorkman P, Cronqvist J, Radstrom P, Holst E: First case of type E wound botulism diagnosed using real-time PCR. J Clin Microbiol 2007,45(11):3589–3594.PubMedCrossRef 9. Sobel J: Botulism. Clin Infect Dis 2005,41(8):1167–1173.PubMedCrossRef 10. Hall JD, McCroskey LM, Pincomb BJ, Hatheway CL: Isolation of an organism resembling Clostridium barati which produces type F botulinal toxin from an infant with botulism.